High Points / Catalyst Stock: ( PMCB ) Continues to move toward a planned Phase 2b clinical trial in LAPC to address patients who no longer see any benefit after being treated for 4-6 months with one of two first-line therapies for the disease. · Its therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. · Successfully completed the crucial pyrogenicity testing that is required by the U.S. Food and Drug Administration (FDA) of the encapsulation material used to manufacture PharmaCyte’s Cell-in-a-Box® capsules · Just entered into a license agreement for CV-19 diagnostics tests
